Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 is a critical piece of legislation in Australia designed to regulate the supply, advertising, and manufacture of therapeutic goods. Enacted to address the need for stringent control and oversight of products that are intended for human use, the Act aims to ensure that these goods are safe, of high quality, and effective. The Therapeutic Goods Administration (TGA), under the auspices of the Department of Health, is the body responsible for administering the Act and ensuring compliance with its provisions. One of the policy objectives stated within the Act is to protect public health by ensuring that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. On 3 March 2020, Katherine Clark, as the Delegate of the Secretary of the Department of Health and the Therapeutic Goods Administration, published the details of a licence granted to Antaria Pty Ltd for the manufacture of therapeutic goods. This notification is part of the ongoing efforts to maintain transparency and accountability in the therapeutic goods industry, ensuring that manufacturers adhere to the rigorous standards set forth by the Therapeutic Goods Act 1989.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide array of entities involved in the manufacture, supply, importation, advertising, or sponsorship of therapeutic goods within Australia. This legislation encompasses both individuals and corporate entities engaged in activities related to therapeutic goods, ensuring that these goods meet the necessary safety, quality, and efficacy standards before they enter the market. The Act extends its jurisdiction across the Commonwealth, providing a unified regulatory framework applicable to all states and territories. However, it does not extend to matters governed by state and territory laws unless specifically authorised by the Therapeutic Goods Act. The scope of the Act is further extended through subordinate instruments, which may include regulations and guidelines that provide additional detail and specificity to the overarching legislative provisions. Notably, certain therapeutic goods and activities may be subject to exclusions or exemptions, which are clearly outlined in the Act or associated regulations, providing a more streamlined regulatory approach for certain lower-risk activities or products.

Key Provisions

Section 38 of the Therapeutic Goods Act 1989 outlines the process for granting a licence to manufacture therapeutic goods, ensuring that only those who meet specific standards and requirements can produce such goods. The Act mandates that the Secretary of the Department of Health, Therapeutic Goods Administration, grants these licences in writing. This particular notification from Katherine Clark, Delegate of the Secretary, confirms that Antaria Pty Ltd has been granted Licence No. MI-2019-LI-01711-1 to manufacture therapeutic goods at their specified location at 1821 Ipswich Road, Rocklea, QLD, 4106. The licence granted to Antaria Pty Ltd imposes several obligations and requirements on the company. These include adherence to Good Manufacturing Practice (GMP) standards, which are designed to ensure that therapeutic goods are produced consistently and with quality. Antaria must maintain detailed records of their manufacturing processes, and they must undergo regular inspections by the Therapeutic Goods Administration to ensure ongoing compliance with the requirements of the licence. Additionally, any changes to their manufacturing processes or premises must be reported to the Therapeutic Goods Administration. Failure to comply with the obligations and requirements set forth in the Therapeutic Goods Act 1989 can lead to serious consequences. Offences under this Act can be both civil and criminal, with penalties that vary depending on the severity of the breach. For example, knowingly supplying a therapeutic good that does not meet the standards set out in the Act can result in a criminal offence. The maximum penalty for this offence is a fine of up to $330,000 for an individual or $1.65 million for a body corporate, or imprisonment for up to five years, or both. Additionally, civil penalties can include fines of up to $1.1 million for serious breaches, and the court can order the cancellation of the licence if the breach is deemed to be of a significant nature.